Literature DB >> 2198074

Functions and relevance of the terminal complement sequence.

S Bhakdi1, F Hugo, J Tranum-Jensen.   

Abstract

The terminal complement sequence is initiated upon cleavage of C5 with liberation of C5a anaphylatoxin, and involves the assembly of macromolecular C5b-9 complexes either on cell surfaces or in plasma. Cell-bound C5b-9 complexes generate transmembrane pores that can cause cell death, or they can elicit secondary cellular reactions triggered, for example, by passive flux of calcium ions into the cells. In vivo functions of the fluid-phase SC5b-9 complex have not yet been defined, but the identity of S-protein with vitronectin (serum spreading factor) provokes the anticipation that significant biological functions of this complex do exist. The terminal complement sequence may fulfil protective functions when it is triggered on alien cells that are marked for destruction. Dysregulation in the complement sequence may, however, result in detrimental attack by C5b-9 on autologous cells. Examples include not only autoimmune disease states, but also the activation of complement on dead or dying cells, and bystander attack on blood cells during cardiopulmonary bypass. Methods for detecting and quantifying C5b-9 are outlined, and the potential usefulness of such assays in clinical research is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2198074     DOI: 10.1007/bf01737843

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  64 in total

1.  The cytolytic C5b-9 complement complex: feedback inhibition of complement activation.

Authors:  S Bhakdi; F Maillet; M Muhly; M D Kazatchkine
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

2.  Haemolytic 'efficiency' of C5b-9 complexes in drug-induced immune haemolysis: role of cellular C5b-9 distribution.

Authors:  A Salama; C Mueller-Eckhardt; B Boschek; S Bhakdi
Journal:  Br J Haematol       Date:  1987-02       Impact factor: 6.998

3.  Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2+.

Authors:  D F Carney; C H Hammer; M L Shin
Journal:  J Immunol       Date:  1986-07-01       Impact factor: 5.422

4.  Complement activation during major operations with or without cardiopulmonary bypass.

Authors:  E Fosse; T E Mollnes; B Ingvaldsen
Journal:  J Thorac Cardiovasc Surg       Date:  1987-06       Impact factor: 5.209

5.  Macrophages release arachidonic acid, prostaglandin E2, and thromboxane in response to late complement components.

Authors:  G M Hänsch; M Seitz; G Martinotti; M Betz; E W Rauterberg; D Gemsa
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

6.  Neoantigens of the membrane attack complex of human complement.

Authors:  W P Kolb; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1975-05       Impact factor: 11.205

7.  A novel beta-endorphin binding protein. Complement S protein (= vitronectin) exhibits specific non-opioid binding sites for beta-endorphin upon interaction with heparin or surfaces.

Authors:  A Hildebrand; K T Preissner; G Müller-Berghaus; H Teschemacher
Journal:  J Biol Chem       Date:  1989-09-15       Impact factor: 5.157

8.  C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.

Authors:  T Kinoshita; Y Takata; H Kozono; J Takeda; K S Hong; K Inoue
Journal:  J Immunol       Date:  1988-12-01       Impact factor: 5.422

9.  Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.

Authors:  S Schönermark; E W Rauterberg; M L Shin; S Löke; D Roelcke; G M Hänsch
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

10.  Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus.

Authors:  R J Falk; A P Dalmasso; Y Kim; S Lam; A Michael
Journal:  N Engl J Med       Date:  1985-06-20       Impact factor: 91.245

View more
  7 in total

1.  Quantitation of vitronectin in serum: evaluation of its usefulness in routine clinical practice.

Authors:  N A Boyd; A R Bradwell; R A Thompson
Journal:  J Clin Pathol       Date:  1993-11       Impact factor: 3.411

2.  Malarial anemia: digestive vacuole of Plasmodium falciparum mediates complement deposition on bystander cells to provoke hemophagocytosis.

Authors:  Prasad Dasari; Anja Fries; Sophia D Heber; Abdulgabar Salama; Igor-Wolfgang Blau; Klaus Lingelbach; Sebastian Chakrit Bhakdi; Rachanee Udomsangpetch; Michael Torzewski; Karina Reiss; Sucharit Bhakdi
Journal:  Med Microbiol Immunol       Date:  2014-07-02       Impact factor: 3.402

3.  The kinetics and distribution of C9 and SC5b-9 in vivo: effects of complement activation.

Authors:  J D Greenstein; P W Peake; J A Charlesworth
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

4.  Gene frequency and partial protein characterization of an allelic variant of mannan binding protein associated with low serum concentrations.

Authors:  P Garred; S Thiel; H O Madsen; L P Ryder; J C Jensenius; A Svejgaard
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

5.  Soluble complex of complement increases hydraulic conductivity in single microvessels of rat lung.

Authors:  S Ishikawa; H Tsukada; J Bhattacharya
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

6.  Complement activation and formation of the membrane attack complex on serogroup B Neisseria meningitidis in the presence or absence of serum bactericidal activity.

Authors:  M Drogari-Apiranthitou; E J Kuijper; N Dekker; J Dankert
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

7.  On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety.

Authors:  S Bhakdi; B Dorweiler; R Kirchmann; J Torzewski; E Weise; J Tranum-Jensen; I Walev; E Wieland
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.